27N0
Cannovum Cannabis AG engages in the manufacturing, wholesaling, and importing of medical cannabis products in Berlin. It also focuses on the import of medical cannabis and medical-scientific education, as well as distribution for facilitated access to cannabis-based therapies. The company was formerly known as Cannovum AG and changed its name to Cannovum Cannabis AG in April 2023. Cannovum Cannab… Read more
27N0 (27N0) - Net Assets
Latest net assets as of December 2023: €136.23K EUR
Based on the latest financial reports, 27N0 (27N0) has net assets worth €136.23K EUR as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€408.08K) and total liabilities (€271.86K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €136.23K |
| % of Total Assets | 33.38% |
| Annual Growth Rate | -76.65% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 45.28 |
27N0 - Net Assets Trend (2020–2023)
This chart illustrates how 27N0's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 27N0 (2020–2023)
The table below shows the annual net assets of 27N0 from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €136.23K | -94.30% |
| 2022-12-31 | €2.39 Million | -79.32% |
| 2021-12-31 | €11.56 Million | +8.36% |
| 2020-12-31 | €10.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 27N0's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 120857300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.42 Million | 1044.02% |
| Total Equity | €136.23K | 100.00% |
27N0 Competitors by Market Cap
The table below lists competitors of 27N0 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Juhayna Food Industries
EGX:JUFO
|
$4.66K |
|
ONCODES.PREC.MED. EO-34
F:ZR8
|
$4.66K |
|
1 Production Film Co.
TWO:8458
|
$4.67K |
|
Viet Brand Invest JSC
VN:ABR
|
$4.67K |
|
Charoen Pokphand Foods PCL
STU:CPOF
|
$4.65K |
|
MICROVISION (MVIN.SG)
STU:MVIN
|
$4.65K |
|
Lords Grp Trading Plc
LSE:LORD
|
$4.65K |
|
BorrowMoney.com Inc
PINK:BWMY
|
$4.65K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 27N0's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 2,391,252 to 136,227, a change of -2,255,025 (-94.3%).
- Net loss of 3,170,025 reduced equity.
- Other factors increased equity by 915,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.17 Million | -2327.02% |
| Other Changes | €915.00K | +671.67% |
| Total Change | €- | -94.30% |
Book Value vs Market Value Analysis
This analysis compares 27N0's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.84x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.02x to 4.84x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | €23.04 | €0.46 | x |
| 2021-12-31 | €24.23 | €0.46 | x |
| 2022-12-31 | €4.71 | €0.46 | x |
| 2023-12-31 | €0.10 | €0.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 27N0 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2327.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -79489.09%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 3.00x
- Recent ROE (-2327.02%) is below the historical average (-685.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -0.29% | -544.02% | 0.00x | 1.00x | €-1.10 Million |
| 2021 | -0.93% | -3060.88% | 0.00x | 1.00x | €-1.26 Million |
| 2022 | -414.95% | 0.00% | 0.00x | 1.12x | €-10.16 Million |
| 2023 | -2327.02% | -79489.09% | 0.01x | 3.00x | €-3.18 Million |
Industry Comparison
This section compares 27N0's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $10,270,247,393
- Average return on equity (ROE) among peers: -102.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 27N0 (27N0) | €136.23K | -0.29% | 2.00x | $4.66K |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |